← FDA DRUG APPROVALS

FDA ANDA · ANDA209624

BOSUTINIB

Sponsor: MSN

APPLICATION
ANDA209624
TYPE
ANDA
ORIGINAL APPROVAL
2026-06-12
LATEST ACTION
2026-06-12
ROUTE
ORAL, FILM COATED
DOSAGE FORM
TABLET
MARKETING STATUS
None (Tentative Approval), Prescription

Products

BOSUTINIBNone (Tentative Approval)
BOSUTINIB MONOHYDRATE EQ 100MG BASE · TABLET · FILM COATED
BOSUTINIBNone (Tentative Approval)
BOSUTINIB MONOHYDRATE EQ 500MG BASE · TABLET · FILM COATED
BOSUTINIB MONOHYDRATEPrescription
BOSUTINIB MONOHYDRATE EQ 400MG BASE · TABLET · ORAL

Approval history

2026-06-12UNKNOWN · Original · standardLetterAP
2026-06-12UNKNOWN · Original · standardTA
VIEW ON DRUGS@FDA ↗

Related on SPEQ

Pharma industryGMP disciplineFDA drug shortagesFDA enforcement & recalls

Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →